Dew, Concerning Imclone, just wondering about the rationale for a possible buyout? I see they're heavily dependent on Erbitux, with most of their efforts going toward expanding its indications. Otherwise the pipeline looks thin/early stage. They have a lot of cash (over 750 mil), and no debt, so with the Erbitux franchise facing significant competition soon, wouldn't it seem logical for them to diversify by acquiring some late stage programs? Perhaps getting a new CEO is part of an overall strategy to achieve that, rather than the idea that Lynch was an obstacle to a buyout. Just curious what evidence there is that the board may want to sell out rather than continue on building the company? Thanks Dew.
